Email Phone Custom Custom

INQUIRE

Please enable JavaScript in your browser to complete this form.

Pranlukast

  • Chemical Name: Pranlukast
  • CAS No.:103177-37-3
  • MF:C27H23N5O4
  • MW:481.5
  • Purity:≥98% or according to customer requested
  • Color: White to off-white
  • Product Categories:Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;
  • Test method: HPLC
Category:

Description

What is Pranlukast?

Pranlukast is a common respiratory drug, it belongs to asthma drugs , it is the cysteinyl leukotrienes (LTs) receptor antagonist and it can bind to LTC4, LTD4, LTE4 receptors selectively to antagonize their effect . Roles and application are similar to zafirlukast. It is clinically used for the prevention of bronchial asthma.

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Introduction

Product Name: Pranlukast
Synonyms: PRANLUKAST; 4-oxo-8-(4-(4-phenylbutoxy)benzoylamino)-2-(tetrazol-5-yl)-4h-1-benzopyranh; emihydrate; pranlukast hydrate; Azlaire
CAS: 103177-37-3
MF: C27H23N5O4
MW: 481.5
EINECS: 808-178-9
Product Categories: API; Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals

      

Chemical Structure

Pranlukast            

Chemical Properties   

Melting point  236-238°C
density  1.374±0.06 g/cm3(Predicted)
storage temp.  Sealed in dry,Store in freezer, under -20°C
pka 4.96±0.10(Predicted)
Merck  14,7710
Pranlukast Uses And Synthesis         

Pranlukast, a novel chromone derivative, was introduced in Japan for the treatment of bronchial asthma and allergic diseases. Pranlukast is a highly potent, selective and competitive antagonist of peptidoleukotrienes with high affinity for the LTD4 receptor. In patients with bronchial asthma, pranlukast was reported to induce significant improvement in both immediate and late asthmatic response induced by antigen. Pranlukast is also being evaluated clinically for the treatment of perennial allergic rhinitis, pediatric asthma, and cutaneous pruritus in dialysis patients. The therapeutic potential of pranlukast in managing irritable bowel syndrome has been suggested.

Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

MSDS: MSDS available.

COA: COA can be available if you send us inquiry.

Email us at: info@maxmedchem.com for more details.

Packaging and Shipping

2023082906101618

2023082906101579

LEAVE MESSAGE

Please enable JavaScript in your browser to complete this form.